Is Negativity of Autoantibodies a Marker of Severity in Auto-immune Hepatitis?

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire de la Guadeloupe

About this trial

Evaluate the proportion of seronegative auto-immune hepatitis and a possible relationship with the severity of the disease. Criteria of severity will be defined by corticodependance, corticoresistance and a severe form of the disease at diagnosis (cirrhosis or fulminant hepatitis). In case of predominant seronegative forms, other auto-antibodies related to this auto-immue hepatitis will be searched.

Eligibility criteria

Qualifiers

- Any patient over 18 years old

Patient followed at Hôpital Saint-Antoine or treated for HAI or in Guadeloupe within the framework of the CCRD Filfoie for an acute or chronic AIH under immunosuppressive treatment

Patient affiliate or beneficiary of a social security scheme

Free, informed and written consent signed by the patient and the investigator

Disqualifiers

Patient under 18 years old

Patient not able to give his/her consent

Viral hepatitis: viruses A to E, Epstein-Barr virus, cytomegalovirus and herpes simplex virus

Isolated primary biliary cholangitis

Trial design

Treatments tested in this trial

  • blood sampling

Treatment groups

100 Participants
are divided into 1 treatment group